W Guy Scott1, Helen M Scott. 1. ScottEconomics, Wellington, New Zealand. ScottEconomics@xtra.co.nz
Abstract
OBJECTIVE: The objective of this study was to compare the potential economic efficiency of third-line treatment of chronic lymphocytic leukaemia (CLL) with alemtuzumab versus fludarabine, cyclophosphamide and rituximab (FCR). METHODS: The target population for this study were patients with CLL who were able to tolerate third-line treatment with either FCR or alemtuzumab. The perspective used was that of the New Zealand Pharmaceutical Management Agency (PHARMAC)/District Health Board. Health outcomes considered were survival time from commencement of treatment and quality-adjusted life-years (QALYs) gained. Average costs and outcomes and incremental cost per patient treated, per survival month and per QALY gained, were calculated. All costs were presented in 2006 New Zealand dollars. RESULTS: Base-case direct medical costs for alemtuzumab per treatment regimen per patient were $NZ15 303 lower than those for FCR. The average direct medical cost per survival month gained for alemtuzumab was $NZ3144 and for FCR was $NZ4101, and the average direct medical cost per QALY gained was $NZ46,016 and for FCR was $NZ60,012. CONCLUSION: Third-line treatment of eligible patients with alemtuzumab was found to be $NZ15,303 less costly than FCR per patient.
OBJECTIVE: The objective of this study was to compare the potential economic efficiency of third-line treatment of chronic lymphocytic leukaemia (CLL) with alemtuzumab versus fludarabine, cyclophosphamide and rituximab (FCR). METHODS: The target population for this study were patients with CLL who were able to tolerate third-line treatment with either FCR or alemtuzumab. The perspective used was that of the New Zealand Pharmaceutical Management Agency (PHARMAC)/District Health Board. Health outcomes considered were survival time from commencement of treatment and quality-adjusted life-years (QALYs) gained. Average costs and outcomes and incremental cost per patient treated, per survival month and per QALY gained, were calculated. All costs were presented in 2006 New Zealand dollars. RESULTS: Base-case direct medical costs for alemtuzumab per treatment regimen per patient were $NZ15 303 lower than those for FCR. The average direct medical cost per survival month gained for alemtuzumab was $NZ3144 and for FCR was $NZ4101, and the average direct medical cost per QALY gained was $NZ46,016 and for FCR was $NZ60,012. CONCLUSION: Third-line treatment of eligible patients with alemtuzumab was found to be $NZ15,303 less costly than FCR per patient.
Authors: Michael J Keating; Nicholas Chiorazzi; Bradley Messmer; Rajendra N Damle; Steven L Allen; Kanti R Rai; Manlio Ferrarini; Thomas J Kipps Journal: Hematology Am Soc Hematol Educ Program Date: 2003
Authors: D Oscier; C Fegan; P Hillmen; T Illidge; S Johnson; P Maguire; E Matutes; D Milligan Journal: Br J Haematol Date: 2004-05 Impact factor: 6.998
Authors: Michael Keating; Stephen Coutré; Kanti Rai; Anders Osterborg; Stefan Faderl; Ben Kennedy; Tom Kipps; Gerald Bodey; John C Byrd; Steven Rosen; Claire Dearden; Martin J S Dyer; Peter Hillmen Journal: Clin Lymphoma Date: 2004-03
Authors: Michael J Keating; Ian Flinn; Vinay Jain; Jacques-Louis Binet; Peter Hillmen; John Byrd; Maher Albitar; Lee Brettman; Pedro Santabarbara; Bret Wacker; Kanti R Rai Journal: Blood Date: 2002-05-15 Impact factor: 22.113
Authors: K R Rai; C E Freter; R J Mercier; M R Cooper; B S Mitchell; E A Stadtmauer; P Santábarbara; B Wacker; L Brettman Journal: J Clin Oncol Date: 2002-09-15 Impact factor: 44.544
Authors: Kathleen M Beusterien; John Davies; Michael Leach; David Meiklejohn; Jessica L Grinspan; Alison O'Toole; Steve Bramham-Jones Journal: Health Qual Life Outcomes Date: 2010-05-18 Impact factor: 3.186
Authors: Luis Felipe Casado; Amparo Burgos; Eva González-Haba; Javier Loscertales; Tania Krivasi; Javier Orofino; Carlos Rubio-Terres; Darío Rubio-Rodríguez Journal: Clinicoecon Outcomes Res Date: 2016-09-21